Sorrento Therapeutics Inc. (SRNE) has acquired exclusive distribution rights to Cynviloq in South America from South Korean based-Samyang Biopharmaceuticals. The drug is marketed in some Asian countries for breast, lung, and ovarian cancer.
Forex – financial instrument.Forex news
Sorrento Therapeutics Inc. (SRNE) has acquired exclusive distribution rights to Cynviloq in South America from South Korean based-Samyang Biopharmaceuticals. The drug is marketed in some Asian countries for breast, lung, and ovarian cancer.